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Background
In patients with chronic infection with hepatitis C virus (HCV) genotype 1 who do not have a sustained response to therapy with peginterferon-ribavirin, outcomes after retreatment are suboptimal. Boceprevir, a protease inhibitor that binds to the HCV nonstructural 3 (NS3) active site, has been suggested as an additional treatment.
Methods
To assess the effect of the combination of boceprevir and peginterferon-ribavirin for retreatment of patients with chronic HCV genotype 1 infection, we randomly assigned patients (in a 1:2:2 ratio) to one of three groups. In all three groups, peg interferon alfa2b and ribavirin were administered for 4 weeks (the leadin period). Subsequently, group 1 (control group) received placebo plus peginterferon-ribavirin for 44 weeks; group 2 received boceprevir plus peginterferon-ribavirin for 32 weeks, and patients with a detectable HCV RNA level at week 8 received placebo plus peg interferon-ribavirin for an additional 12 weeks; and group 3 received boceprevir plus peginterferon-ribavirin for 44 weeks. M ore than 170 million people are chronically infected with hepatitis C virus (HCV) worldwide. 1 The standard treatment is combination therapy with peginter feron and ribavirin. [2] [3] [4] Of the six HCV genotypes, genotype 1 is the least responsive to currently approved therapies, with rates of sustained viro logic response of less than 50%. 2, [5] [6] [7] Thus, there is a large population of patients with few thera peutic options, and directacting antiviral thera py has become the focus of investigations re garding treatment for HCV infection. [8] [9] [10] [11] Boceprevir is a structurally novel peptidomi metic ketoamide protease inhibitor that binds reversibly to the HCV nonstructural 3 (NS3) ac tive site. 8 Boceprevir has demonstrated antiviral activity in phase 2 studies of both patients in fected with HCV genotype 1 who have not received prior treatment and those who have received prior treatment. 8 The primary objective of this phase 3 study of patients with previously treated HCV genotype 1 infection was to compare the safety and efficacy of two therapeutic regimens of bo ceprevir in combination with peginterferon and ribavirin to therapy with peginterferon and riba virin alone. The safety and efficacy of boceprevir in previously untreated patients are described in the article by Poordad and colleagues in this is sue of the Journal. 12 
Me thods
Study Oversight
The study protocol is available with the full text of this article at NEJM.org. The trial (HCV RESPOND2 [Retreatment with HCV Serine Pro tease Inhibitor Boceprevir and PegIntron/Rebetol 2]) was funded by ScheringPlough (now part of Merck) and was designed, managed, and analyzed by Merck in conjunction with the external aca demic investigators and members of the external data and safety monitoring board. The academic authors had agreements with the sponsor con cerning the confidentiality of the data. The aca demic authors collected the data, which was then analyzed by the sponsor. The sponsor held the data and made them available to the academic authors. The first draft of the manuscript was written by one academic author and three industry authors. All authors were involved in the collec tion, analysis, or interpretation of the data; revi sion of the manuscript; and the decision to submit the manuscript for publication. All authors vouch for the completeness and accuracy of the data and analyses as well as the fidelity of the study to the protocol.
Study Patients
From August through November 2008, we screened 640 patients with HCV genotype 1 infection at 80 sites in North America and Europe. Eligibil ity criteria included demonstrated responsive ness to interferon (minimum duration of therapy, 12 weeks). We defined patients as having either nonresponse (i.e., a decrease in the HCV RNA level of at least 2 log 10 IU per milliliter by week 12 but with a detectable HCV RNA level during the therapy period) or relapse (i.e., an undetectable HCV RNA level at the end of treatment, without subsequent attainment of a sustained virologic response [i.e., with a detectable HCV RNA level during the followup period]).
Exclusion criteria included hepatitis B or infec tion with the human immunodeficiency virus, any other cause of clinically significant liver disease, decompensated liver disease, uncontrolled dia betes mellitus, a severe psychiatric disorder, and active substance abuse. Liverbiopsy specimens were assessed for Metavir fibrosis scores and ste atosis scores by a single academic author who is a pathologist and was unaware of the assignment of boceprevir or placebo. Possible Metavir fibro sis scores are as follows: a score of 0 indicates no fibrosis, 1 indicates portal fibrosis without septa, 2 indicates portal fibrosis with few septa, 3 indi cates numerous septa without cirrhosis, and 4 in dicates cirrhosis.
Study Design
The primary objective was to compare two treat ment regimens containing boceprevir in combi nation with openlabel peginterferon alfa2b and ribavirin (PegIntron and Rebetol, respectively; Merck) to treatment with peginterferon-ribavi rin plus placebo in previously treated adults with chronic HCV genotype 1 infection. Our study was conducted in accordance with the principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies. All patients provided writ ten informed consent before randomization.
Patients were randomly assigned, in a 1:2:2 ratio with the use of an interactive voiceresponse system, to one of three treatment groups, with stratification according to previous response to therapy (nonresponse or relapse) and HCV sub genotype (1a or 1b) as determined by means of sequencing of the HCV 5′ noncoding region (Tru gene). 13 Patients with HCV genotype 1 infection whose HCV subtype could not be classified were randomly assigned to one of the treatment groups. The HCV genotype 1 subtype was also determined by means of sequencing of the nonstructural 5B (NS5B) region (Virco).
The study design is illustrated in Figure 1 . For purposes of the study doses, peginterferon alfa2b was administered subcutaneously at a dose of 1.5 μg per kilogram of body weight once weekly, and ribavirin was administered at a divided daily dose of 600 to 1400 mg per day on the basis of body weight. Treatment with boceprevir consisted of oral administration at a dose of 800 mg three times daily (to be taken with food and with an interval of 7 to 9 hours between doses) in four capsules of 200 mg each. Placebo was matched to boceprevir. The study was doubleblinded regard ing the administration of boceprevir.
During For 13 patients for whom the HCV RNA measurement at the end of the follow-up period was missing, the measurement obtained at 12 weeks of follow-up was carried forward; of these patients, a sustained virologic response was achieved in 2 (1 in group 2 and 1 in group 3). Patients with a detectable HCV RNA level at week 12 were considered to have had treatment failure (according to the stopping rule). Patients in group 1 were offered the opportunity to receive treatment with boceprevir plus peginterferon-ribavirin by means of an access study or to proceed to the followup phase of this study. Patients in groups 2 and 3 proceeded to the follow-up phase of this study. The primary efficacy end point was assessed at the end of the follow-up phase. The x-axis numbers are not to scale. for decision making at various points through out the study. 13 Measurement was performed at the screening visit, at baseline, every 2 weeks through week 12, and then at weeks 16, 20, 24, 30, 36, 42 , and 48, as well as at weeks 4, 12, and 24 of the followup period.
Safety
Adverse events were graded by investigators ac cording to a modified World Health Organiza tion grading system. Non-lifethreatening ad verse events were managed by means of dose reduction. The recommended guidelines for a twostep dose reduction of peginterferon and for a threestep dose reduction of ribavirin were sim ilar to those previously described (as is summa rized in the Supplementary Appendix, available at NEJM.org). 7,14-16 Viral breakthrough was defined as achieve ment of an undetectable HCV RNA level and subsequent occurrence of an HCV RNA level greater than 1000 IU per milliliter. Incomplete virologic response and rebound was defined as an increase of 1 log 10 IU per milliliter in the HCV RNA level from the nadir, with an HCV RNA level greater than 1000 IU per milliliter (if both samples being compared were collected the same number of days after the last peginterferon injection). In cases in which the timing between the peginterferon injection and the HCV RNA sample collection was different for the two sam ples, an increase of 2 log 10 IU per milliliter was required to meet this criterion. If a patient had virologic breakthrough or an incomplete viro logic response and rebound while receiving ther apy, boceprevir treatment could be discontinued, but peginterferon-ribavirin could be continued for up to 48 weeks with appropriate clinical followup.
Statistical Analysis
Analyses regarding the primary objective includ ed data from all patients who received at least one dose of any study medication. The key second ary objective was to compare the two boceprevir regimens with the peginterferon-ribavirin regi men in patients who completed the leadin period and received at least one dose of placebo or bo ceprevir. Specifically, comparisons for the pri mary and key secondary objectives were made between group 3 and group 1 and between group 2 and group 1.
The primary efficacy end point was a sus tained virologic response, defined as an undetect able plasma HCV RNA level at week 24 of the followup period. Secondary and other efficacy analyses were performed to calculate the propor tion of patients with an early response (i.e., an undetectable HCV RNA level at week 8) in whom a sustained virologic response was achieved, as well as the proportion of patients with a relapse.
The primary statistical comparison was car ried out with the use of a twosided CochranMantel-Haenszel chisquare test with adjustment for the baseline stratification factors. The study had a statistical power of 90% to detect an ab solute improvement in the rate of sustained viro logic response by 21 percentage points over the rate in group 1 (assuming response rates of 22% in the control group and 43% in the boceprevir groups) with the use of a twosided chisquare test and an alpha value of 0.05.
To control for type I error in the primary analysis, a stepdown approach was used. Group 3 was first compared against group 1. If the P value for the comparison was less than 0.05, the next comparison -of group 2 and group 1 -was carried out. A similar stepdown approach was prespecified to control for the type I error re garding the key secondary objective. To account for multiplicity between the primary and key secondary analyses, the key secondary analyses were conducted only if the significance of the primary comparisons was established. P values calculated for sustained virologic response are provided for only the two prespecified primary and key secondary comparisons.
Summary statistics are reported for each of the three treatment regimens for subgroups of patients defined according to prespecified base line characteristics. Multivariable logisticregres sion analyses involving treatment regimen and prespecified baseline characteristics were per formed to evaluate sustained virologic respons es. A stepwise procedure was used to identify independent predictors of sustained virologic response (with P = 0.05 as the threshold level for variables to be entered into the model and re tained in the final model). In addition, we fit a stepwise logisticregression model of the re sponse (decrease from baseline in the HCV RNA level of ≥1.0 log 10 IU per milliliter vs. <1.0 log 10 IU per milliliter) at treatment week 4 and base line characteristics. 
R e sult s
Baseline Characteristics
A total of 640 patients were evaluated for enroll ment in the study; 403 were enrolled and under went randomization and treatment (Fig. S1 in the Supplementary Appendix). The baseline demo graphic characteristics were balanced among the three treatment groups (Table 1) , with the excep tion of high viral load (group 2 vs. group 1, P = 0.04). The mean age was 52.7 years, 12% of patients were black, and the mean body weight was 84.9 kg. Approximately 88% of patients had a high viral load (an HCV RNA level >800,000 IU per milliliter) at baseline. The prevalence of in fection with HCV genotypes 1a and 1b was simi lar (47% and 44%, respectively). A total of 19% of patients had a Metavir fibrosis score of 3 or 4.
The majority of patients (64%) had had a relapse after previous HCV therapy.
Efficacy
In the primaryanalysis population, rates of sus tained virologic response were significantly high er among patients receiving boceprevir than among those treated with peginterferon-ribavirin alone (Fig. 2) , with overall rates of sustained virologic response of 21%, 59%, and 66% in groups 1, 2, and 3, respectively (P<0.001). This increase seen with boceprevir was due largely to endoftreat ment rates of response (i.e., an undetectable HCV RNA level) that were greater in group 2 (70%) and group 3 (77%) than in group 1 (31%) The rates of sustained virologic response among patients with prior relapse were 29% in group 1, versus 69% and 75% in group 2 and group 3, respectively; among patients with prior nonre sponse, the corresponding rates were 7% versus 40% and 52%. A total of 102 patients (15%, 28%, and 27% in groups 1, 2, and 3, respectively) had a poor response to interferon, defined as a decrease in the HCV RNA level of less than 1 log 10 IU per milliliter after the 4week leadin period (Fig. 2) .
In this subgroup, a sustained virologic response was achieved in none of the patients in group 1 and in 33% and 34% in groups 2 and 3, respec tively. Among patients who had a good response to interferon (a decrease in HCV RNA level of 1 log 10 IU per milliliter or more at treatment week 4), the rates of sustained virologic response were 25%, 73%, and 79% in group 1, group 2, and group 3, respectively.
An assessment for amino acid variants associ ated with reduced susceptibility to boceprevir was performed for 114 patients in group 2 or group 3 in whom a sustained virologic response did not occur. Postbaseline data were available for 98 of the 114 patients (86%), with variants detected in 43 of these 98 patients (44%). The rate of amino acid variants associated with reduced susceptibil ity to boceprevir was higher among patients with a poor response to interferon (13 An evaluation of treatment effect according to subgroups of baseline characteristics showed that the numerical odds of a sustained virologic response was greater, across all subgroups, with either responseguided triple therapy (group 2) or 44week triple therapy (group 3) than with the standard of care (group 1) (Fig. 3) .
Although there was a sustained virologic re sponse in 12 more patients in group 3 than in group 2, the rates in each group did not differ significantly (odds ratio of a sustained virologic response in group 3 vs. group 2, 1.4; 95% confi dence interval, 0.9 to 2.2). A similarly small dif ference was seen between these two groups dur * ALT denotes alanine aminotransferase, and HCV hepatitis C virus. † Race was self-reported. ‡ The body-mass index is the weight in kilograms divided by the square of the height in meters. § The HCV subtype was ascertained by means of sequencing of the nonstructural 5B (NS5B) region. ¶ Eligibility criteria included an absolute neutrophil count of 1500 per cubic millimeter or higher for nonblacks and 1200 per cubic millimeter or higher for blacks, a platelet count of 100,000 per cubic millimeter or higher, and a hemoglobin level of 12 g per deciliter or more for women and 13 g per deciliter or more for men. ‖ For a viral load >800,000 IU per milliliter, P = 0.04 for the comparison of group 2 versus group 1. ** Metavir scores and percent steatosis were determined on the basis of assessment of liver-biopsy specimens by a single pathologist who was unaware of the assignment to boceprevir or placebo. A total of 28 patients (4 in group 1, 13 in group 2, and 11 in group 3) had missing data regarding these characteristics. Possible fibrosis scores are as follows: 0 (indicating no fibrosis), 1 (indicating portal fibrosis without septa), 2 (indicating portal fibrosis with few septa), 3 (indicating numerous septa without cirrhosis), and 4 (indicating cirrhosis). † † Prior nonresponse was defined as a decrease in the HCV RNA level of at least 2 log 10 IU per milliliter by week 12 of prior therapy but a detectable HCV RNA level throughout the course of prior therapy, without subsequent attainment of a sustained virologic response. Prior relapse was defined as an undetectable HCV RNA level at the end of prior therapy, without subsequent attainment of a sustained virologic response.
The New England Journal of Medicine The percentages of patients with a sustained virologic response are shown. The prespecified primary analysis involved all patients who were randomly assigned to a treatment group and received at least one dose of any study medication. The prespecified secondary analysis involved all patients who were randomly assigned to a treatment group and received at least one dose of boceprevir or placebo. Prior relapse was defined as an undetectable HCV RNA level at the end of prior therapy without subsequent attainment of a sustained virologic response. Prior nonresponse was defined as a decrease in the HCV RNA level of at least 2 log 10 IU per milliliter by week 12 of prior therapy but a detectable HCV RNA level throughout the course of prior therapy, without subsequent attainment of a sustained virologic response. Poor response to interferon was defined as a decrease in the HCV RNA level of less than 1 log 10 IU per milliliter after the 4-week lead-in period (treatment week 4). Good response to interferon was defined as a decrease in HCV RNA level of 1 log 10 IU per milliliter or more after the lead-in period. For the primary analysis, the absolute difference between group 2 and group 1 was 37. either boceprevir group rather than the control group (odds ratios for group 2 and group 3 vs. group 1, 7.3 and 10.7, respectively; P<0.001 for both comparisons), previous relapse (odds ratio vs. previous nonresponse, 3.1; P<0.001), low vi ral load at baseline (odds ratio vs. high load, 2.5; P = 0.02), and absence of cirrhosis (odds ratio vs. presence, 2.1; P = 0.04) ( Table S1 in the Supple mentary Appendix). When the decline in viral load (i.e., decrease from baseline in the HCV RNA level of ≥1.0 log 10 IU per milliliter vs. <1.0 log 10 IU per milliliter) at week 4 (was added to the model, the week 4 response was a stronger predictor of sustained virologic response than historical re sponse (odds ratio, 5.2; P<0.001).
Safety
The study included a stopping rule whereby pa tients in whom an undetectable HCV RNA level was not achieved by treatment week 12 discon tinued all therapy. The low rate of an undetect able HCV RNA level by treatment week 12 in group 1 resulted in 61% of patients discontinu ing treatment for this reason, as compared with 22% and 18% of patients in group 2 and group 3, respectively ( Fig. S1 in the Supplementary Appen dix). Thus, the median duration of treatment was 2.4 to 3.2 times longer in the boceprevir groups than in the control group (Table 2 ). In the boceprevir groups as compared with the control group, a greater proportion of pa tients reported serious adverse events and there were more discontinuations and dose modifica tions owing to adverse events. There was a higher incidence of anemia in the groups receiving boceprevir (43 to 46%) than in the control group (20%). Consistent with the increased incidence of anemia, the proportion of patients with hemo globin levels of 6.5 to less than 9.5 g per deciliter was higher in groups 2 and 3 than in group 1; however, discontinuation owing to anemia was infrequent (occurring in 0% of patients group 1 and group 2 and in 3% [5 of 161 patients] in group 3). Erythropoietin was administered to 21%, 41%, and 46% of patients in groups 1, 2, and 3, respectively. Of the 403 patients, 17 received a transfusion for the management of anemia; 16 of these patients also received erythropoietin. Ad verse events, dose modifications, and studydrug discontinuation in the 49 patients with cirrhosis are summarized in Table S3 in the Supplemen tary Appendix.
The most common adverse events observed in all treatment groups were flulike symptoms that are typically reported in association with pegin terferon-ribavirin therapy (Table S5 in the Sup  plementary Appendix) . Dysgeusia, rash, and dry skin were reported more commonly in the boce previr groups than in the control group.
Discussion
Our data show that the addition of boceprevir to peginterferon-ribavirin therapy leads to high rates of sustained virologic response among pa tients in whom prior treatment had failed. Fur thermore, patients who had previously had a re lapse after receiving the standard of care had rates of sustained virologic response of up to 75%, with rates of 40 to 52% in the subgroup of pa tients with a previous nonresponse. Patients with undetectable HCV RNA levels at treatment week 8 were shown to have a rate of sustained viro logic response that was similar whether bocepre vir was taken for 32 weeks or 44 weeks; thus, an early response identified patients who could ben efit from shorter treatment. There were no iden tified groups of patients with a previous treat ment failure for whom the standard of care was more efficacious than was triple therapy. We ob served high rates of a sustained virologic response among black patients and patients with advanced liver disease, who usually have a poor response, 17, 18 Odds ratios are shown for group 3 versus group 1 (solid circles) and group 2 versus group 1 (open circles) on a log 10 scale. The dashed vertical line at unity indicates no difference between the two groups (odds ratio of 1). The dashed horizontal arrows indicate odds ratios and confidence intervals that exceed the x-axis scale. Race was self-reported. The body-mass index (BMI) is the weight in kilograms divided by the square of the height in meters. For the Metavir fibrosis score, presence or absence of cirrhosis, and percent steatosis, a total of 28 patients (4 in group 1, 13 in group 2, and 11 in group 3) had missing data. Data on sustained virologic response for other subgroups are listed in Table S2 of the Supplementary Appendix. P values for the interaction between treatment group and baseline characteristic are given in Table 6 representing a clinically significant improvement over the standard of care. 19 Rates of anemia were higher among patients receiving boceprevircontaining regimens than among those receiving control therapy, and many patients required erythropoietin treatment. Dis continuation for anemia was infrequent (affect ing 3% of patients in group 3 only). Consistent with the increased incidence of anemia, a higher proportion of boceprevir recipients, as compared with controls, had a neutrophil count of 500 to less than 750 per cubic millimeter or underwent a redcell transfusion.
This study included a 4week leadin period Table S4 in the Supplementary Appendix. The P values presented are nominal, have not been adjusted for multiple comparisons, and are based on Fisher's exact test for categorical variables and Student's t-test for continuous variables. † There was one death by suicide in group 2, which occurred 18 weeks after the end of the study treatment and was considered to be unrelated to the study treatment. ‡ Common adverse events were those classified as being related to a study treatment and occurring with an incidence of 15% or more in any group. Only common adverse events for which P<0.05 for a pairwise comparison with group 1 (group 3 vs. group 1 or group 2 vs. group 1) are shown. All other common adverse events (for which the treatmentrelated incidence was 15% or more in any group) can be found in Table S5 during which peginterferon-ribavirin was admin istered, which allowed for the assessment of the patient's interferon responsiveness immediately before the addition of boceprevir. We have previ ously shown that a decline in viral load of less than 1 log 10 IU per milliliter after 4 weeks of peginterferon-ribavirin therapy is significantly correlated to a decline of less than 2 log 10 IU per milliliter after 12 weeks of treatment. 20 We iden tified 102 patients with a poor response to inter feron, defined as a decrease in the HCV RNA level of less than 1 log 10 IU per milliliter at week 4. This is an important recognition of the changes that can evolve over time in patients who had previously been treated and are awaiting retreat ment. Possible explanations for such changes include an increase in body weight, development of glucose intolerance, an increase in hepatic steatosis, and progression of fibrosis, all of which could have resulted in diminished responsiveness to peginterferon-ribavirin. Notably, a sustained virologic response was achieved, after boceprevir was added to the standard of care, in 33 to 34% of the patients with a poor response to inter feron, as compared with 0% in the patients re treated with peginterferon-ribavirin alone. In summary, the results of our phase 3 trial show that boceprevir, when added to peginter feron alfa2b and ribavirin, leads to high rates of sustained virologic response in difficultto treat patients.
